VKTX: Obesity program VK2735 advances in phase III with broad market and manufacturing strategies
Lead obesity candidate VK2735 is advancing through phase III trials in both injectable and oral forms, with maintenance and dosing flexibility studies underway. Manufacturing capacity and commercialization strategies are robust, and policy, pricing, and AI adoption are closely monitored for future…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.